George Vrachiolias
Overview
Explore the profile of George Vrachiolias including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
29
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chatzikonstantinou T, Scarfo L, Minga E, Karakatsoulis G, Chamou D, Kotaskova J, et al.
Hemasphere
. 2024 Sep;
8(9):e70004.
PMID: 39290716
No abstract available.
2.
Karatisidis L, Zagoridis K, Mprotsis T, Misidou C, Pentidou A, Vrachiolias G, et al.
Thromb Res
. 2024 May;
238:88-96.
PMID: 38696925
Introduction: Recommendations about proper anticoagulation in obese patients, body mass index (BMI) > 30 kg/m2, are not yet clearly defined. Obese patients were included in randomized controlled trials comparing new...
3.
Chatzikonstantinou T, Scarfo L, Karakatsoulis G, Minga E, Chamou D, Iacoboni G, et al.
EClinicalMedicine
. 2023 Nov;
65:102307.
PMID: 38033506
Background: Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed...
4.
Moysiadis T, Koparanis D, Liapis K, Ganopoulou M, Vrachiolias G, Katakis I, et al.
iScience
. 2023 Sep;
26(9):107591.
PMID: 37664638
Personalized prediction is ideal in chronic lymphocytic leukemia (CLL). Although refined models have been developed, stratifying patients in risk groups, it is required to accommodate time-dependent information of patients, to...
5.
Mitroulis I, Papadopoulos V, Lamprianidou E, Mirtschink P, Liapis K, Zafeiropoulou K, et al.
Blood Cancer J
. 2023 May;
13(1):64.
PMID: 37137883
No abstract available.
6.
Liapis K, Papadopoulos V, Pontikoglou C, Vrachiolias G, Stavroulaki E, Kourakli A, et al.
Leukemia
. 2023 Jan;
37(3):708-711.
PMID: 36646886
No abstract available.
7.
Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
Liapis K, Papadopoulos V, Vrachiolias G, Galanopoulos A, Papoutselis M, Papageorgiou S, et al.
Blood Cancer J
. 2021 Feb;
11(2):30.
PMID: 33574231
No abstract available.
8.
Papadopoulos V, Diamantopoulos P, Papageorgiou S, Papoutselis M, Vrachiolias G, Pappa V, et al.
Hematol Oncol
. 2020 Jun;
38(4):541-553.
PMID: 32495951
Higher-risk Myelodysplastic syndromes (MDS) patients undergoing treatment with 5-azacytidine (AZA) are typically elderly with several comorbidities. However, the effect of comorbidities on the effectiveness and safety of AZA in real-world...
9.
Kazachenka A, Young G, Attig J, Kordella C, Lamprianidou E, Zoulia E, et al.
Genome Med
. 2019 Dec;
11(1):86.
PMID: 31870430
Background: Myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) are characterised by abnormal epigenetic repression and differentiation of bone marrow haematopoietic stem cells (HSCs). Drugs that reverse epigenetic repression, such...
10.
Christoforidou A, Bezirgiannidou Z, Vrachiolias G, Papoutselis M, Spanoudakis E, Kotsianidis I
Leuk Lymphoma
. 2019 Nov;
61(3):749-752.
PMID: 31713446
No abstract available.